Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Memo Therapeutics
Biotech
Memo pushes kidney drug to phase 3 despite primary endpoint miss
A phase 2 trial of Memo’s kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication.
Nick Paul Taylor
Jul 25, 2025 5:30am
Trevena teeters on edge with C-suite shakedown—Chutes & Ladders
Nov 8, 2024 8:30am
Kurma closes first $154M haul for biggest biotech fund yet
Oct 3, 2024 8:05am
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Feb 9, 2024 9:30am
Prepping the next generation of COVID-19 vaccines and treatments
May 17, 2021 9:25am
